Hansa Biopharma AB

Hansa Biopharma develops IgG‑cleaving enzyme therapeutics for transplant and rare autoimmune diseases, with Phase II Imlifidase for kidney transplantation and a next‑generation HNSA‑5487 platform, supported by strategic collaborations with Sarepta, AskBio and Genethon.

Headquarters: Sweden (SWE)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 133
HQ: Lund

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
HNSA	Hansa Biopharma AB Cap: 3.6B	EQUITY	STO	SEK	SE0002148817	Active	📈